FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2008
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

PAREKH RAJESH R

2. Date of Event Requiring Statement (MM/DD/YYYY)
3/7/2008 

3. Issuer Name and Ticker or Trading Symbol

AVANT IMMUNOTHERAPEUTICS INC [AVAN]

(Last)        (First)        (Middle)

C/O AVANT IMMUNOTHERAPEUTICS, INC., 119 FOURTH AVENUE

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                            _____ 10% Owner
_____ Officer (give title below)          _____ Other (specify below)

(Street)

NEEDHAM, MA 02494       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock, par value $0.001 per share   56223   I   See footnote   (1)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   9/7/2008   3/7/2018   Common Stock   17879   (2) $8.16   D    

Explanation of Responses:
( 1)  An entity owned in part by Dr. Rajesh B. Parekh and his spouse is entitled to receive 56,223 shares of common stock, par value $0.001 per share (the "Shares") of AVANT Immunotherapeutics, Inc upon the planned liquidation of Lorantis Holdings Limited during 2008. Mr. Parekh disclaims beneficial ownership of these Shares and is not involved in any decision making with respect to the disposition of these Shares.
( 2)  As of March 7, 2008 (the "Effective Date"), Dr. Rajesh B. Parekh beneficially owns options to purchase 17,879 Shares. Options to purchase 11,368 Shares are exercisable as of the Effective Date. Options to purchase 6,511 Shares will be exercisable on the six-month anniversary of the Effective Date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
PAREKH RAJESH R
C/O AVANT IMMUNOTHERAPEUTICS, INC.
119 FOURTH AVENUE
NEEDHAM, MA 02494 		X



Signatures
/s/ Rajesh B. Parekh 3/17/2008
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Avant Immunotherapeutics (MM) (NASDAQ:AVAND)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Avant Immunotherapeutics (MM) Charts.
Avant Immunotherapeutics (MM) (NASDAQ:AVAND)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Avant Immunotherapeutics (MM) Charts.